7-day versus 14-day tegoprazan-based triple therapy to treat Helicobacter pylori infection: Real-world evidence.
Yoon Suk JungSunyong KimHyun-Young KimSeung Jae NohJung Ho ParkChan Hyuk ParkPublished in: Journal of gastroenterology and hepatology (2022)
The 14-day tegoprazan-based triple therapy showed a superior eradication rate and acceptable adverse events compared with the 7-day tegoprazan-based triple therapy. A 14-day treatment regimen may be required when H. pylori infection is treated with tegoprazan-based triple therapy in regions with high clarithromycin resistance.